Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells
Grasberger, B.L., Lu, T., Schubert, C., Parks, D.J., Carver, T.E., Koblish, H.K., Cummings, M.D., LaFrance, L.V.(2005) J Med Chem 48: 909-912
- PubMed: 15715460 
- DOI: https://doi.org/10.1021/jm049137g
- Primary Citation of Related Structures:  
1T4E, 1T4F - PubMed Abstract: 
HDM2 binds to an alpha-helical transactivation domain of p53, inhibiting its tumor suppressive functions. A miniaturized thermal denaturation assay was used to screen chemical libraries, resulting in the discovery of a novel series of benzodiazepinedione antagonists of the HDM2-p53 interaction. The X-ray crystal structure of improved antagonists bound to HDM2 reveals their alpha-helix mimetic properties. These optimized molecules increase the transcription of p53 target genes and decrease proliferation of tumor cells expressing wild-type p53.
Organizational Affiliation: 
Johnson & Johnson Pharmaceutical Research & Development L.L.C., 665 Stockton Drive, Exton, Pennsylvania 19341, USA. bgrasber@prdus.jnj.com